Lotus Reports April 2026 Revenue of NT$3,086 Million

Taipei, Taiwan, 11 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenue for April 2026 of NT$3,086 million, representing an increase of 20% YoY, mainly driven by the consolidation of Alvogen. Lotus' year-to-date (YTD) April 2026 revenue reached NT$11,730 million, an increase of 61% compared to the same period last year, continued to be supported by Alvogen as well as strong growth in the B2B business.

For the first four months ending April 2026, revenue from US grew 99% YoY to NT$6,976 million for the period, representing c.60% of the total consolidated revenue, driven by the consolidation of Alvogen beginning December 2025. Lotus’ Asia business grew 3% YoY to NT$3,626 million, representing c.31% of the Group’s total consolidated revenue, mainly supported by continued growth in the Southeast Asia market, which increased 18% YoY. Lotus’ B2B business grew 317% YoY to NT$1,128 million, contributing c.10% of total consolidated revenue, supported by key product launches such as Nintedanib in EU as well as Enzalutamide in South America and Canada.

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness